Published in Clin Exp Metastasis on January 01, 2002
Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br J Cancer (2007) 1.61
Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays. Hum Pathol (2009) 1.08
Measurement of circulating levels of VEGF-A, -C, and -D and their receptors, VEGFR-1 and -2 in gastric adenocarcinoma. World J Gastroenterol (2008) 1.07
Imbalance of angiopoietin-1 and angiopoetin-2 in severe dengue and relationship with thrombocytopenia, endothelial activation, and vascular stability. Am J Trop Med Hyg (2012) 0.98
Real-time PCR of CD146 mRNA in peripheral blood enables the relative quantification of circulating endothelial cells and is an indicator of angiogenesis. Br J Cancer (2005) 0.97
The role of targeted therapy and biomarkers in breast cancer treatment. Clin Exp Metastasis (2012) 0.96
Differential changes in platelet VEGF, Tsp, CXCL12, and CXCL4 in patients with metastatic cancer. Clin Exp Metastasis (2010) 0.95
VEGF concentration from plasma-activated platelets rich correlates with microvascular density and grading in canine mast cell tumour spontaneous model. J Cell Mol Med (2008) 0.88
The relation of serum vascular endothelial growth factor level with disease duration and activity in patients with rheumatoid arthritis. Clin Rheumatol (2010) 0.87
Roles of vascular endothelial growth factor in amyotrophic lateral sclerosis. Biomed Res Int (2014) 0.79
Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid. BMC Cancer (2011) 0.78
Clinical significance of serum biomarkers in pediatric solid mediastinal and abdominal tumors. Int J Mol Sci (2012) 0.77
Predictive value of tumor recurrence using urinary vascular endothelial factor levels in patients receiving radiation therapy for Glioblastoma Multiforme (GBM). Biomark Res (2013) 0.76
Association of plasma VEGF-A, soluble VEGFR-1 and VEGFR-2 levels and clinical response and survival in advanced colorectal cancer patients receiving bevacizumab with modified FOLFOX6. Oncol Lett (2010) 0.76
Angiogenic factors in serum of patients with testicular germ cell tumours. Urol Res (2004) 0.75
Plasma Vascular Endothelial Growth Factor Concentration and Alveolar Nitric Oxide as Potential Predictors of Disease Progression and Mortality in Idiopathic Pulmonary Fibrosis. J Clin Med (2016) 0.75
Methodological concerns regarding levels of vascular endothelial growth factor (VEGF) in serum of women with endometriosis. Int J Fertil Steril (2015) 0.75
Serum VEGF, blood transfusion, and wound orientation : Letter re: Belizon et al. Surg Endosc. 2008 Jan 18. Surg Endosc (2008) 0.75
Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med (1991) 19.46
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (1993) 15.70
Molecular and biological properties of vascular endothelial growth factor. J Mol Med (Berl) (1999) 4.85
Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer (1998) 3.93
Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci U S A (1997) 3.30
Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging? Clin Cancer Res (2000) 2.95
Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int (1999) 2.68
Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol (1995) 2.52
Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res (1995) 2.34
Vascular endothelial growth factor platelet counts, and prognosis in renal cancer. Lancet (1999) 2.26
Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin Cancer Res (1999) 2.18
Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer (1999) 2.17
Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res (2000) 2.12
Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J Natl Cancer Inst (1995) 2.07
Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res (2000) 1.88
Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst (1997) 1.87
Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. Br J Cancer (1999) 1.81
Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol (1995) 1.81
Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb Haemost (1998) 1.80
Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Br J Haematol (1999) 1.77
Tumoural vascularity as a prognostic factor in cancer patients: the evidence continues to grow. J Pathol (1998) 1.77
Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res (1997) 1.74
Blood platelets and serum VEGF in cancer patients. Br J Cancer (1999) 1.66
Intracellular pool of vascular endothelial growth factor in human neutrophils. Blood (1997) 1.64
Vascular endothelial growth factor. Eur J Cancer (1996) 1.58
Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer (1997) 1.54
In vitro release of vascular endothelial growth factor during platelet aggregation. Am J Physiol (1998) 1.54
A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood (1997) 1.51
Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. Clin Sci (Lond) (1998) 1.46
High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int J Cancer (1998) 1.40
Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol (2000) 1.35
Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Clin Cancer Res (1997) 1.32
Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res (1998) 1.29
Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood. Oncology (2000) 1.23
Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer. Ann Oncol (1996) 1.16
Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia. Br J Haematol (1999) 1.15
The salvaged blood syndrome: a sequel to mechanochemical activation of platelets and leukocytes? Blood Cells (1990) 1.13
Vascular endothelial growth factor serum concentrations in ovarian cancer. Obstet Gynecol (1998) 1.13
Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to study an angiogenic marker in vivo? Ann Oncol (1999) 1.13
Clinical prognostic significance of tumour angiogenesis. Ann Oncol (1994) 1.11
Prognostic value of tumour vascularity in metastatic melanoma and association of blood vessel density with vascular endothelial growth factor expression. Melanoma Res (1999) 1.11
Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: which is the optimal specimen? Int J Oncol (2000) 1.10
Proinflammatory mediators stimulate neutrophil-directed angiogenesis. Arch Surg (1999) 1.08
Serum VEGF levels in women with a benign breast tumor or breast cancer. Breast Cancer Res Treat (1999) 1.05
Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma. Cancer Lett (2000) 1.03
Tumor Growth: A Putative Role for Platelets? Oncologist (1998) 0.98
Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival. Gynecol Oncol (1999) 0.97
Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients. Anticancer Res (1998) 0.89
Vascular endothelial growth factor in premenopausal women--indicator of the best time for breast cancer surgery? Br J Cancer (1998) 0.89
Anti-angiogenesis therapy and strategies for integrating it with adjuvant therapy. Recent Results Cancer Res (1998) 0.86
Large amounts of vascular endothelial growth factor at the site of hemostatic plug formation in vivo. Arterioscler Thromb Vasc Biol (1999) 0.85
Major surgery increases serum levels of vascular endothelial growth factor only temporarily. Am J Surg (2000) 0.84
The impact and management of anaemia in haematological malignancies. Med Oncol (2000) 0.84
Epoetin in cancer-related anaemia. Nephrol Dial Transplant (1999) 0.83
Evaluation of recombinant human erythropoietin to facilitate autologous blood donation before surgery in anaemic patients with cancer of the gastrointestinal tract. Br J Surg (1995) 0.83
Haematological variables in prostatic carcinoma patients. Acta Urol Belg (1996) 0.81
The effect of storage on degranulation by human neutrophils. Transfusion (1985) 0.81
Circulating vascular endothelial growth factor (VEGF) is not a prognostic indicator in malignant melanoma. Cancer Lett (1998) 0.81
Cooling and freezing damage platelet membrane integrity. Cryobiology (1999) 0.80
Serum concentrations of vascular endothelial growth factor in vulvar cancer. Clin Cancer Res (1999) 0.77
Platelets and VEGF blood levels in cancer patients. Br J Cancer (1999) 0.76
Serum vascular endothelial growth factor load and interleukin-6 in cancer patients. Br J Cancer (2000) 0.76
On a possible interaction between ADP and mechanical stimulation in platelet activation. Thromb Haemost (1984) 0.76
Prolonged holding of whole blood at 22 degrees C does not increase activation in platelet concentrates. Vox Sang (1997) 0.75
RADIOACTIVE IODINE AS AN INDICATOR IN THYROID PHYSIOLOGY. IV. THE METABOLISM OF IODINE IN GRAVES' DISEASE. J Clin Invest (1942) 11.36
Translational control is required for the unfolded protein response and in vivo glucose homeostasis. Mol Cell (2001) 11.21
Lay people's attitudes to treatment of depression: results of opinion poll for Defeat Depression Campaign just before its launch. BMJ (1996) 6.31
Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res (2000) 5.74
Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci U S A (1997) 5.42
Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res (1996) 5.38
The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol (2000) 5.21
An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell (2001) 4.79
Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet (1990) 4.49
GALEN ten years on: tasks and supporting tools. Stud Health Technol Inform (2001) 4.34
Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet (1987) 4.28
Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet (1992) 4.10
Equilibrium properties of a voltage-dependent junctional conductance. J Gen Physiol (1981) 3.91
Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry (2000) 3.89
Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha. Blood (1998) 3.67
Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res (1989) 3.35
Kinetic properties of a voltage-dependent junctional conductance. J Gen Physiol (1981) 3.33
HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res (2001) 3.27
Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer (2001) 3.10
Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer (1996) 3.07
Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer (2002) 2.82
Alpha 1-adrenoceptor subtypes linked to different mechanisms for increasing intracellular Ca2+ in smooth muscle. Nature (1987) 2.80
Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet (1985) 2.76
Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol (2001) 2.71
Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res (2001) 2.66
Gap junctional conductance is a simple and sensitive function of intracellular pH. Science (1981) 2.64
eIF4E expression in tumors: its possible role in progression of malignancies. Int J Biochem Cell Biol (1999) 2.57
Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol (1995) 2.52
Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br J Cancer (1999) 2.47
Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis (2008) 2.45
Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer. Lancet (1985) 2.44
Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res (2001) 2.38
Transient increase in phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol trisphosphate during activation of human neutrophils. J Biol Chem (1989) 2.35
Dual-component amino-acid-mediated synaptic potentials: excitatory drive for swimming in Xenopus embryos. J Physiol (1985) 2.34
c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer (1991) 2.29
Vascular endothelial growth factor platelet counts, and prognosis in renal cancer. Lancet (1999) 2.26
Hemolysin production as a virulence marker in symptomatic and asymptomatic urinary tract infections caused by Escherichia coli. Infect Immun (1983) 2.26
Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer (1996) 2.23
Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Res (1994) 2.21
Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer (2003) 2.20
Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol (1997) 2.19
Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. J Pathol (2000) 2.18
Macrophage responses to hypoxia: relevance to disease mechanisms. J Leukoc Biol (1999) 2.17
Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. J Pathol (2000) 2.11
Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer. J Clin Pathol (2005) 2.10
Discovery of a Jupiter/Saturn analog with gravitational microlensing. Science (2008) 2.09
Isoform composition of connexin channels determines selectivity among second messengers and uncharged molecules. J Biol Chem (1998) 2.08
An audit of clinical nurse practitioner led thrombolysis to improve the treatment of acute myocardial infarction. J Public Health Med (2000) 2.08
An inositol tetrakisphosphate-containing phospholipid in activated neutrophils. Nature (1988) 2.07
Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J Natl Cancer Inst (1995) 2.07
The use of gemeprost pessaries to arrest postpartum haemorrhage. Br J Obstet Gynaecol (1993) 2.04
Comparison of alpha 1-adrenergic receptor subtypes distinguished by chlorethylclonidine and WB 4101. Mol Pharmacol (1988) 2.04
Secretion of epidermal growth factor by macrophages associated with breast carcinoma. Lancet (1993) 2.03
Are we educating a medical professional who cares? Am J Dis Child (1992) 2.02
Make an application for flexible (part time) training. BMJ (1995) 2.02
Assessing traumatic event exposure: general issues and preliminary findings for the Stressful Life Events Screening Questionnaire. J Trauma Stress (1998) 2.01
Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family. Infect Immun (1999) 1.95
Regulation of autophagy by ATF4 in response to severe hypoxia. Oncogene (2010) 1.93
Voltage dependence of junctional conductance in early amphibian embryos. Science (1979) 1.90
A role for the human DNA repair enzyme HAP1 in cellular protection against DNA damaging agents and hypoxic stress. Nucleic Acids Res (1994) 1.89
Quantitative optical phase microscopy. Opt Lett (1998) 1.88
A precision measurement of the mass of the top quark. Nature (2004) 1.87
Screening for neural-tube defects and maternal anxiety. Br J Obstet Gynaecol (1982) 1.86
Selectivity of connexin-specific gap junctions does not correlate with channel conductance. Circ Res (1995) 1.84
Epidermal growth factor receptors in non-small cell lung cancer. Br J Cancer (1987) 1.83
Prospective study of healthcare utilisation and respiratory morbidity due to RSV infection in prematurely born infants. Thorax (2005) 1.83
Targeting gene expression to hypoxic tumor cells. Nat Med (1997) 1.82
Academe and government. Firm link or broken reed? West J Med (1993) 1.81
Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol (1995) 1.81
bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer (1994) 1.81
The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. Br J Cancer (2011) 1.77
Paraneoplastic myasthenic syndrome IgG inhibits 45Ca2+ flux in a human small cell carcinoma line. Nature (1985) 1.76
Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br J Cancer (2010) 1.74
Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24. Nucleic Acids Res (1992) 1.74
Differential expression of human Wnt genes 2, 3, 4, and 7B in human breast cell lines and normal and disease states of human breast tissue. Cancer Res (1994) 1.72
Expression of vascular endothelial growth factor D is associated with hypoxia inducible factor (HIF-1alpha) and the HIF-1alpha target gene DEC1, but not lymph node metastasis in primary human breast carcinomas. J Clin Pathol (2004) 1.72
Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. Am J Pathol (2001) 1.71
Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful? Breast Cancer Res Treat (1998) 1.70
Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst (1999) 1.70
Gating of gap junction channels. Biophys J (1984) 1.70
The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer (1990) 1.69
Sensory physiology, anatomy and immunohistochemistry of Rohon-Beard neurones in embryos of Xenopus laevis. J Physiol (1984) 1.68
Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. Br J Cancer (2003) 1.67
Direct observations of ligand dynamics in hemoglobin by subpicosecond infrared spectroscopy. Proc Natl Acad Sci U S A (1989) 1.67
Cytokine networks in solid human tumors: regulation of angiogenesis. J Leukoc Biol (1994) 1.66
hAG-2 and hAG-3, human homologues of genes involved in differentiation, are associated with oestrogen receptor-positive breast tumours and interact with metastasis gene C4.4a and dystroglycan. Br J Cancer (2003) 1.65
Aortic root dilatation and mitral valve prolapse in Marfan's syndrome: an ECHOCARDIOgraphic study. Circulation (1975) 1.63
Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol (2001) 1.62
Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer (1992) 1.62
Relationship of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. Cancer Res (2000) 1.60
New insights into the physiological role of carbonic anhydrase IX in tumour pH regulation. Oncogene (2010) 1.60
The Schizosaccharomyces pombe cdc5+ gene encodes an essential protein with homology to c-Myb. EMBO J (1994) 1.59
Quantitative assays of epidermal growth factor receptor in human breast cancer: cut-off points of clinical relevance. Int J Cancer (1988) 1.59
Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer. Cancer Res (1993) 1.58
Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge. J Virol (2001) 1.58
In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin Exp Immunol (2010) 1.58